Procopio, Giuseppe

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 5,807

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

Cited by 977

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 736

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., et al. (2022) · NEJM Evidence

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 426

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 326

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 140

Coronavirus: older persons with cancer in Italy in the COVID-19 pandemic

Fratino, L., Procopio, G., Di Maio, M., Cinieri, S., Leo, S., & Beretta, G. (2020) · Frontiers in Oncology

COVID-19 and healthcare impactsFrailty in Older Adults

Cited by 28